Tue Jan 13 14:05:21 UTC 2026: # Counterfeit Epilepsy Medication Seized in Telangana, India

The Story:

The Drugs Control Administration (DCA), Telangana, seized a substantial quantity of counterfeit ‘Levipil 500’ tablets during raids conducted across the state on Tuesday, January 13, 2026. Levipil 500 is a widely prescribed medication for the treatment of epilepsy. The fake tablets were falsely branded as a product of Sun Pharma Laboratories Ltd. The DCA acted on specific intelligence indicating the presence of these spurious drugs in the market.

Key Points:

  • The seized tablets were falsely labeled as ‘Levipil 500’, a medicine used to treat epilepsy.
  • Raids were conducted by the DCA at drug dealers’ outlets across Telangana.
  • The counterfeit drugs were found at Durga Medical and General Stores in Sudharsan Reddy Nagar, Chintal.
  • The counterfeit tablets bore batch number GTF0885A, with a false manufacturing date of April 2024 and an expiry date of March 2026.
  • The packaging falsely claimed the drug was manufactured by Sun Pharma Laboratories Ltd in Kokjhar village, Kamrup district, Assam.
  • The public is urged to report suspected illegal drug activities to the DCA‘s toll-free helpline: 1800-599-6969.

Critical Analysis:

While the provided context is diverse, it does not directly reveal any strategic depth related to the counterfeit drug seizure. The other news items appear unrelated, covering topics such as prison inspections, theft, US politics, and local student unrest. Therefore, it is difficult to establish any meaningful patterns or connections without further information.

Key Takeaways:

  • The presence of counterfeit drugs poses a significant threat to public health in Telangana.
  • The DCA is actively working to combat the distribution of spurious medications.
  • Consumers are urged to be vigilant and report any suspected counterfeit drugs.
  • The investigation will likely focus on tracing the source and distribution network of the fake Levipil 500 tablets.
  • Stringent legal action is expected against those involved in the manufacturing and sale of the counterfeit drugs.

    Read More

Related News: